Therna’s RNA Intelligence Platform integrates advanced AI models with deep RNA biology and in-house experimental validation to rapidly design, test, and optimize programmable RNA medicines.
The Only AI Platform Designed for Both mRNA and ASO / siRNA Therapeutics
CONTEXT
RNA is studied in relation
to its environment
THERNA
MULTI-LAYERED DATA
Proprietary experimental data
generated to feed models
THERNA
FOUNDATION
BIOLOGY AI
Stackable predictive models built to
address unique aspects of RNA biology
THERNA
GENERATIVE AI FOR
RNA MEDICINE
Generative Al models for mRNA
design and target selection
OUTPUT
Testing and validation of our
De nevo designs
The Only AI Platform Desgined for Both mRNA and ASO / siRNA Therapeutics
CONTEXT
RHA is studied in relation
to its environment
THERNA
MULTI-LAYERED DATA
Proprietary experimental data
generated to feed models
THERNA
FOUNDATION
BIOLOGY AI
Stackable predictive models built to
address unique aspects of RNA biology
THERNA
GENERATIVE AI FOR
RNA MEDICINE
Generative Al models for mRNA
design and Target Selection
OUTPUT
Testing and validation of our
de nevo designs
RNA-Logix™ Platform Capabilities
Biology-guided AI design grounded in deep RNA expertise
Lab-in-the-loop validation to test and refine designs in real time
Faster path from sequence to molecule through integrated execution
Continuously improving models informed by experimental data
Programmable control of RNA behavior across modalities and diseases
Language Models
mRNA
Therna develops RNA language models trained on large-scale experimental datasets to understand how mRNA sequence design influences translation, stability, immune response, and tissue and cell specificity. These models enable precise control over coding sequence optimization, allowing mRNA therapeutics to be precisely engineered for predictable and durable performance.
ASOs and siRNA
For antisense oligonucleotides (ASOs) and siRNA, Therna’s models identify optimal target sites and sequence features that drive effective silencing, upregulation, and fine-tuning of genes. By learning directly from functional RNA data, the platform supports rational design of ASO and siRNA therapies with improved potency, specificity, and consistency.
Lab-in-the-Loop
RNA-Logix™ is built around a lab-in-the-loop approach, where AI-driven RNA designs are evaluated using high-quality, proprietary experimental datasets generated through in-house testing in primary cells and relevant In Vivo preclinical models. These experimental results are continuously fed back into the models, strengthening predictive accuracy with every iteration. This iterative system enables faster learning, reduced uncertainty, and a more reliable path from sequence design to validated therapeutic candidates.
RNA-Logix™ Platform
Understanding
RNA Medicines
Therna uses its proprietary RNA-Logix™ platform to design across the full spectrum of RNA medicines. Each modality offers a different way to influence biology.
Modality 01
mRNA
Messenger RNA carries instructions that direct cells to make a specific protein. It can be used to restore or boost a beneficial protein the body needs.
Modality 02
ASOs
Antisense oligonucleotides are short, single-stranded sequences that bind a target RNA to adjust how a gene is expressed, including dialing a protein down or, in Therna's differentiated approach, switching it up.
Modality 03
siRNAs
Small interfering RNAs are short, double-stranded sequences that selectively silence a target gene to reduce the production of a disease-causing protein.
Because ASOs and siRNAs act with high precision, they can reach disease drivers conventional drugs can't. By first unlocking the underlying biology, RNA-Logix™ learns where and how to intervene, then designs potential new medicines across all three modalities: mRNA, ASOs, and siRNAs.
